COLD + SINUS DAYTIME TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Verfügbar ab:

VITA HEALTH PRODUCTS INC

ATC-Code:

M01AE51

INN (Internationale Bezeichnung):

IBUPROFEN, COMBINATIONS

Dosierung:

200MG; 30MG

Darreichungsform:

TABLET

Zusammensetzung:

IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

10/20/24/40/50/72/96/100

Verschreibungstyp:

OTC

Therapiebereich:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0222394001; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2011-02-08

Fachinformation

PRODUCT MONOGRAPH
COLD + SINUS DAYTIME
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
Caplets
Analgesic/Antipyretic/Nasal Decongestant
COLD + SINUS NIGHTTIME
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
and Chlorpheniramine Maleate 2 mg
Tablets
Analgesic/Antipyretic/Nasal Decongestant/Antihistamine
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
October 19, 2020
Winnipeg, Manitoba Canada, R2J 3W2
Control # 239435
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
5
ADVERSE REACTIONS
.......................................................................................................................
13
DRUG INTERACTIONS
........................................................................................................................
23
DOSAGE AND ADMINISTRATION
....................................................................................................
27
OVERDOSAGE
......................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
31
STORAGE AND STABILITY
...............................................................................................................
36
SPECIAL HANDLING INSTRUCTIONS
....................................